ID: ALA346303

Max Phase: Preclinical

Molecular Formula: C19H18N2O2

Molecular Weight: 306.37

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCC=C1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O

Standard InChI:  InChI=1S/C19H18N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-14H,2-3H2,1H3

Standard InChI Key:  LFSPRCNNTHTFOX-UHFFFAOYSA-N

Associated Targets(Human)

Cyclooxygenase 1258 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 306.37Molecular Weight (Monoisotopic): 306.1368AlogP: 3.71#Rotatable Bonds: 4
Polar Surface Area: 40.62Molecular Species: HBA: 2HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 3.99CX LogD: 3.99
Aromatic Rings: 2Heavy Atoms: 23QED Weighted: 0.64Np Likeness Score: 0.11

References

1. Vennerstrom JL, Holmes TJ..  (1987)  Preparation and evaluation of electrophilic derivatives of phenylbutazone as inhibitors of prostaglandin-H synthase.,  30  (3): [PMID:3102742] [10.1021/jm00386a020]

Source